|
1.
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Haass NK and Herlyn M: Normal human
melanocyte homeostasis as a paradigm for understanding melanoma. J
Investig Dermatol Symp Proc. 10:153–163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Haass NK, Smalley KS and Herlyn M: The
role of altered cell– cell communication in melanoma progression. J
Mol Histol. 35:309–318. 2004.
|
|
4.
|
Wang Q, Sun ZX, Allgayer H, et al:
Downregulation of E-cadherin is an essential event in activating
beta-catenin/Tcf-dependent transcription and expression of its
target genes in Pdcd4 knockdown cells. Oncogene. 29:128–138. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Shibahara K, Asano M, Ishida Y, et al:
Isolation of a novel mouse gene MA-3 that is induced upon
programmed cell death. Gene. 166:297–301. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Jansen AP, Camalier CE and Colburn NH:
Epidermal expression of the translation inhibitor programmed cell
death 4 suppresses tumorigenesis. Cancer Res. 65:6034–6041. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Soejima H, Miyoshi O, Yoshinaga H, et al:
Assignment of the programmed cell death 4 gene (PDCD4) to human
chromosome band 10q24 by in situ hybridization. Cytogenet Cell
Genet. 87:113–114. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Cmarik JL, Min H, Hegamyer G, et al:
Differentially expressed protein PDCD4 inhibits tumor
promoter-induced neoplastic transformation. Proc Natl Acad Sci USA.
96:14037–14042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Chang JH, Cho YH, Sohn SY, et al: Crystal
structure of the eIF4A-PDCD4 complex. Proc Natl Acad Sci USA.
106:3148–3153. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Suzuki C, Garces RG, Edmonds KA, et al:
PDCD4 inhibits translation initiation by binding to eIF4A using
both its MA3 domains. Proc Natl Acad Sci USA. 105:3274–3279. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Yang HS, Cho MH, Zakowicz H, et al: A
novel function of the MA-3 domains in transformation and
translation suppressor Pdcd4 is essential for its binding to
eukaryotic translation initiation factor 4A. Mol Cell Biol.
24:3894–3906. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Zakowicz H, Yang HS, Stark C, et al:
Mutational analysis of the DEAD-box RNA helicase eIF4AII
characterizes its interaction with transformation suppressor Pdcd4
and eIF4GI. RNA. 11:261–274. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
LaRonde-LeBlanc N, Santhanam AN, Baker AR,
et al: Structural basis for inhibition of translation by the tumor
suppressor Pdcd4. Mol Cell Biol. 27:147–156. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chen Y, Knosel T, Kristiansen G, et al:
Loss of PDCD4 expression in human lung cancer correlates with
tumour progression and prognosis. J Pathol. 200:640–646. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Zhang H, Ozaki I, Mizuta T, et al:
Involvement of programmed cell death 4 in transforming growth
factor-beta1-induced apoptosis in human hepatocellular carcinoma.
Oncogene. 25:6101–6112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Afonja O, Juste D, Das S, et al: Induction
of PDCD4 tumor suppressor gene expression by RAR agonists,
antiestrogen and HER-2/neu antagonist in breast cancer cells.
Evidence for a role in apoptosis. Oncogene. 23:8135–8145. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mudduluru G, Medved F, Grobholz R, et al:
Loss of programmed cell death 4 expression marks adenoma-carcinoma
transition, correlates inversely with phosphorylated protein kinase
B, and is an independent prognostic factor in resected colorectal
cancer. Cancer. 110:1697–1707. 2007. View Article : Google Scholar
|
|
18.
|
Motoyama K, Inoue H, Mimori K, et al:
Clinicopathological and prognostic significance of PDCD4 and
microRNA-21 in human gastric cancer. Int J Oncol. 36:1089–1095.
2010.PubMed/NCBI
|
|
19.
|
Jin H, Kim TH, Hwang SK, et al: Aerosol
delivery of urocanic acid-modified chitosan/programmed cell death 4
complex regulated apoptosis, cell cycle, and angiogenesis in lungs
of K-ras null mice. Mol Cancer Ther. 5:1041–1049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Jansen AP, Camalier CE, Stark C, et al:
Characterization of programmed cell death 4 in multiple human
cancers reveals a novel enhancer of drug sensitivity. Mol Cancer
Ther. 3:103–110. 2004.PubMed/NCBI
|
|
21.
|
Caporali S, Alvino E, Levati L, et al:
Down-regulation of the PTTG1 proto-oncogene contributes to the
melanoma suppressive effects of the cyclin-dependent kinase
inhibitor PHA-848125. Biochem Pharmacol. 84:598–611. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Yang CH, Yue J, Pfeffer SR, et al:
MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma
cells. J Biol Chem. 286:39172–39178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Rothhammer T, Hahne JC, Florin A, et al:
The Ets-1 transcription factor is involved in the development and
invasion of malignant melanoma. Cell Mol Life Sci. 61:118–128.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Amara A, Gall SL, Schwartz O, et al: HIV
coreceptor down-regulation as antiviral principle:
SDF-1alpha-dependent internalization of the chemokine receptor
CXCR4 contributes to inhibition of HIV replication. J Exp Med.
186:139–146. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, et al: miRBase: microRNA sequences, targets and gene
nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Betel D, Wilson M, Gabow A, et al: The
microRNA. org resource: targets and expression Nucleic Acids Res.
36:D149–D153. 2008.PubMed/NCBI
|
|
27.
|
Lankat-Buttgereit B and Goke R: The tumour
suppressor Pdcd4: Recent advances in the elucidation of function
and regulation. Biol Cell. 101:309–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Allgayer H: Pdcd4, a colon cancer
prognostic that is regulated by a microRNA. Crit Rev Oncol Hematol.
73:185–191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Yang HS, Jansen AP, Nair R, et al: A novel
transformation suppressor, Pdcd4, inhibits AP-1 transactivation but
not NF-κB or ODC transactivation. Oncogene. 20:669–676.
2001.PubMed/NCBI
|
|
30.
|
Schmid T, Jansen AP, Baker AR, et al:
Translation inhibitor Pdcd4 is targeted for degradation during
tumor promotion. Cancer Res. 68:1254–1260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Leupold JH, Yang HS, Colburn NH, et al:
Tumor suppressor Pdcd4 inhibits invasion/intravasation and
regulates urokinase receptor (u-PAR) gene expression via
Sp-transcription factors. Oncogene. 26:4550–4562. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Böhm M, Sawicka K, Siebrasse JP, et al:
The transformation suppressor protein Pdcd4 shuttles between
nucleus and cytoplasm and binds RNA. Oncogene. 22:4905–4910.
2003.PubMed/NCBI
|
|
33.
|
Yang HS, Jansen AP, Komar AA, et al: The
transformation suppressor Pdcd4 is a novel eukaryotic translation
initiation factor 4A binding protein that inhibits translation. Mol
Cell Biol. 23:26–37. 2003. View Article : Google Scholar
|
|
34.
|
Tawbi HA and Kirkwood JM: Management of
metastatic melanoma. Semin Oncol. 34:532–545. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Gibbs DF, Warner RL, Weiss SJ, et al:
Characterization of matrix metalloproteinases produced by rat
alveolar macrophages. Am J Respir Cell Mol Biol. 20:1136–1144.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Shah PK, Falk E, Badimon JJ, et al: Human
monocyte-derived macrophages induce collagen breakdown in fibrous
caps of atherosclerotic plaques. Potential role of matrix-degrading
metal-loproteinases and implications for plaque rupture.
Circulation. 92:1565–1569. 1995.
|
|
37.
|
Jackson C, Nguyen M, Arkell J, et al:
Selective matrix metalloproteinase (MMP) inhibition in rheumatoid
arthritis-targetting gelatinase A activation. Inflamm Res.
50:183–186. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Balkwill F: The significance of cancer
cell expression of the chemokine receptor CXCR4. Semin Cancer Biol.
14:171–179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Kucia M, Jankowski K, Reca R, et al:
CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol
Histol. 35:233–245. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Schimanski CC, Schwald S, Simiantonaki N,
et al: Effect of chemokine receptors CXCR4 and CCR7 on the
metastatic behavior of human colorectal cancer. Clin Cancer Res.
11:1743–1750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Harvey JR, Mellor P, Eldaly H, et al:
Inhibition of CXCR4-mediated breast cancer metastasis: a potential
role for heparinoids? Clin Cancer Res. 13:1562–1570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Zhou W, Jiang Z, Liu N, et al:
Down-regulation of CXCL12 mRNA expression by promoter
hypermethylation and its association with metastatic progression in
human breast carcinomas. J Cancer Res Clin Oncol. 135:91–102. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Turner RR, Ye X, Bilchik AJ, et al:
Chemokine receptor CXCR4 expression in patients with melanoma and
colorectal cancer liver metastases and the association with disease
outcome. Ann Surg. 244:113–120. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Scala S, Giuliano P, Ascierto PA, et al:
Human melanoma metastases express functional CXCR4. Clin Cancer
Res. 12:2427–2433. 2006. View Article : Google Scholar : PubMed/NCBI
|
